● Recruiting

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

Condition: Breast Cancer · Sponsor: Shengjing Hospital

PhaseN/A

Planned participants200

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.

This description comes directly from the study's public registry record.

Talk to the study team

Nan Niu, MD · +8618940256668 · niunannancy@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05263570